/IKT
IKT Stock - Inhibikase Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.72+2.99%
+$0.05 (+2.99%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+132.6%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IKT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.70 – $1.74
TARGET (TP)$4.00
STOP LOSS$1.58
RISK/REWARD1:16.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.88
52W High$3.49
52W Low$1.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $260,500 | $123,440 | $3.10M | $698,468 |
| Gross Profit | $-26,272 | $-13,357,848 | $116,717 | $-8,258,499 | $-195,334 |
| Gross Margin | N/A | -5127.8% | 94.6% | -266.4% | -28.0% |
| Operating Income | $-28,589,068 | $-20,089,792 | $-18,128,608 | $-14,766,140 | $-2,818,492 |
| Net Income | $-27,519,886 | $-19,028,883 | $-18,054,155 | $-14,786,063 | $-2,847,894 |
| Net Margin | N/A | -7304.8% | -14625.9% | -476.9% | -407.7% |
| EPS | $-1.16 | $-3.57 | $-4.26 | $-4.88 | $-1.72 |
Company Overview
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish1 Neutral/Bearish
Price Targets
$4
Average Target
↑ 132.6% Upside
Now
$4
Low
$4
Average
$4
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Cantor Fitzgerald | Initiation | Overweight | $4 |
| February 12th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
Earnings History & Surprises
IKTBeat Rate
18%
Last 17 quarters
Avg Surprise
-253.0%
EPS vs Estimate
Beats / Misses
3/13
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+19.2%
$-0.63vs$-0.78
Q2 24
+7.6%
$-0.73vs$-0.79
Q3 24
-13.8%
$-0.66vs$-0.58
Q4 24
-71.1%
$-0.65vs$-0.38
Q1 25
-530.0%
$-0.63vs$-0.10
Q2 25
-36.4%
$-0.15vs$-0.11
Q3 25
-22.2%
$-0.11vs$-0.09
Q4 25
0.0%
$-0.13vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.10 | $-0.63 | -530.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.38 | $-0.65 | -71.1% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.58 | $-0.66 | -13.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.79 | $-0.73 | +7.6% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.78 | $-0.63 | +19.2% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.12 | $-0.86 | +23.2% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.92 | $-1.11 | -20.7% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.14 | $-1.02 | -628.6% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | — | $-0.20 | — | — |
Q4 2022 | Nov 14, 2022 | $-0.18 | $-1.08 | -500.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.19 | $-1.08 | -468.4% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.17 | $-1.08 | -535.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.17 | $-1.20 | -605.9% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.14 | $-1.08 | -671.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.38 | $-1.32 | -247.4% | ✗ MISS |
Q2 2021 | May 17, 2021 | — | $-1.56 | — | — |
Latest News
Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program
➖ NeutralBenzinga•Dec 19, 2025, 09:30 PM
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4
📈 PositiveBenzinga•Dec 11, 2025, 02:57 PM
Reported Earlier, Inhibikase Therapeutics Prices $100M Offering Of 46,091,739 Common Shares At $1.45 And 22,873,779 Pre Funded Warrants At $1.449
📉 NegativeBenzinga•Nov 21, 2025, 08:11 AM
Inhibikase Therapeutics shares are trading lower after the company announced an offering of common stock and pre-funded warrants.
📉 NegativeBenzinga•Nov 20, 2025, 09:15 PM
Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed
➖ NeutralBenzinga•Nov 20, 2025, 09:14 PM
Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Global Phase 3 Trial And Is Expected To Begin In Q1 2026
📈 PositiveBenzinga•Nov 20, 2025, 09:04 PM
Inhibikase Therapeutics Q3 EPS $(0.13), Inline
➖ NeutralBenzinga•Nov 14, 2025, 09:03 PM
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise
📈 PositiveSeeking Alpha•Apr 14, 2025, 12:19 PM
Frequently Asked Questions about IKT
What is IKT's current stock price?
Inhibikase Therapeutics, Inc. (IKT) is currently trading at $1.72 per share. The stock has moved +2.99% today.
What is the analyst price target for IKT?
The average analyst price target for IKT is $4.00, based on 1 analyst.
What sector is Inhibikase Therapeutics, Inc. in?
Inhibikase Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IKT's market cap?
Inhibikase Therapeutics, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does IKT pay dividends?
No, Inhibikase Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
ENTX
Entera Bio Ltd.
$1.77
Mkt Cap: $0.1B
ESLA
Estrella Immunopharma, Inc.
$1.69
Mkt Cap: $0.1B
EXOZ
eXoZymes, Inc.
$12.30
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TTRX
Turn Therapeutics Inc.
$3.00
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
Explore stocks similar to IKT for comparison